Preclinical studies of fluvastatin

Alberto Corsini, Remo Fumagalli, Rodolfo Paoletti, Franco Bernini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fluvastatin is the first entirely synthetic inhibitor of HMG-CoA reductase that has been extensively investigated. According to the studies presented in this review, fluvastatin is a potent inhibitor of HMG-CoA reductase in vitro, a potent inhibitor of cholesterol biosynthesis in cultured cells and in vivo in rats, and a potent hypocholesterolemic agent in several animal species. Inhibition of liver cholesterol synthesis by fluvastatin leads to increased expression of LDL receptors on the cell surface. This in turn leads to increased turnover in circulating LDL particles, thus decreasing total blood cholesterol. The observation that fluvastatin, beyond its lipid-lowering effect, at therapeutic concentrations may affect early events of atherogenesis by inhibiting arterial myocyte migration and proliferation and by interfering with cellular cholesterol disposition, adds antiatherosclerotic properties to this drug. Fluvastatin possesses pharmacokinetic properties desirable for inhibitors of HMG-CoA reductase, and thus of cholesterol biosynthesis. Fluvastatin is almost completely absorbed after oral administration in all species, is largely extracted and biotransformed by the liver, and exhibits a short half-life. Furthermore, a major portion of fluvastatin and its metabolites is preferentially excreted into bile, thus minimizing the systemic burden. The drug and its metabolites are readily excreted and show no retention in body tissues. Safety of fluvastatin after acute and chronic administration was evaluated in various animal species. The results indicate that fluvastatin has different species-specific target organs at doses many times higher than those estimated in man. In conclusion, fluvastatin is a well tolerated and highly effective drug. Thus, it may be considered an important drug in the therapeutic armamentarium available for the treatment of hypercholesterolemia and for the prevention of atherosclerosis.

Original languageEnglish
Pages (from-to)13-35
Number of pages23
JournalDrugs of Today
Volume32
Issue numberSUPPL A
Publication statusPublished - 1996

Fingerprint

fluvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol
Pharmaceutical Preparations
Atherosclerosis
Anticholesteremic Agents

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Corsini, A., Fumagalli, R., Paoletti, R., & Bernini, F. (1996). Preclinical studies of fluvastatin. Drugs of Today, 32(SUPPL A), 13-35.

Preclinical studies of fluvastatin. / Corsini, Alberto; Fumagalli, Remo; Paoletti, Rodolfo; Bernini, Franco.

In: Drugs of Today, Vol. 32, No. SUPPL A, 1996, p. 13-35.

Research output: Contribution to journalArticle

Corsini, A, Fumagalli, R, Paoletti, R & Bernini, F 1996, 'Preclinical studies of fluvastatin', Drugs of Today, vol. 32, no. SUPPL A, pp. 13-35.
Corsini A, Fumagalli R, Paoletti R, Bernini F. Preclinical studies of fluvastatin. Drugs of Today. 1996;32(SUPPL A):13-35.
Corsini, Alberto ; Fumagalli, Remo ; Paoletti, Rodolfo ; Bernini, Franco. / Preclinical studies of fluvastatin. In: Drugs of Today. 1996 ; Vol. 32, No. SUPPL A. pp. 13-35.
@article{2445bfe3ee054413b2256abe1c61b023,
title = "Preclinical studies of fluvastatin",
abstract = "Fluvastatin is the first entirely synthetic inhibitor of HMG-CoA reductase that has been extensively investigated. According to the studies presented in this review, fluvastatin is a potent inhibitor of HMG-CoA reductase in vitro, a potent inhibitor of cholesterol biosynthesis in cultured cells and in vivo in rats, and a potent hypocholesterolemic agent in several animal species. Inhibition of liver cholesterol synthesis by fluvastatin leads to increased expression of LDL receptors on the cell surface. This in turn leads to increased turnover in circulating LDL particles, thus decreasing total blood cholesterol. The observation that fluvastatin, beyond its lipid-lowering effect, at therapeutic concentrations may affect early events of atherogenesis by inhibiting arterial myocyte migration and proliferation and by interfering with cellular cholesterol disposition, adds antiatherosclerotic properties to this drug. Fluvastatin possesses pharmacokinetic properties desirable for inhibitors of HMG-CoA reductase, and thus of cholesterol biosynthesis. Fluvastatin is almost completely absorbed after oral administration in all species, is largely extracted and biotransformed by the liver, and exhibits a short half-life. Furthermore, a major portion of fluvastatin and its metabolites is preferentially excreted into bile, thus minimizing the systemic burden. The drug and its metabolites are readily excreted and show no retention in body tissues. Safety of fluvastatin after acute and chronic administration was evaluated in various animal species. The results indicate that fluvastatin has different species-specific target organs at doses many times higher than those estimated in man. In conclusion, fluvastatin is a well tolerated and highly effective drug. Thus, it may be considered an important drug in the therapeutic armamentarium available for the treatment of hypercholesterolemia and for the prevention of atherosclerosis.",
author = "Alberto Corsini and Remo Fumagalli and Rodolfo Paoletti and Franco Bernini",
year = "1996",
language = "English",
volume = "32",
pages = "13--35",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "SUPPL A",

}

TY - JOUR

T1 - Preclinical studies of fluvastatin

AU - Corsini, Alberto

AU - Fumagalli, Remo

AU - Paoletti, Rodolfo

AU - Bernini, Franco

PY - 1996

Y1 - 1996

N2 - Fluvastatin is the first entirely synthetic inhibitor of HMG-CoA reductase that has been extensively investigated. According to the studies presented in this review, fluvastatin is a potent inhibitor of HMG-CoA reductase in vitro, a potent inhibitor of cholesterol biosynthesis in cultured cells and in vivo in rats, and a potent hypocholesterolemic agent in several animal species. Inhibition of liver cholesterol synthesis by fluvastatin leads to increased expression of LDL receptors on the cell surface. This in turn leads to increased turnover in circulating LDL particles, thus decreasing total blood cholesterol. The observation that fluvastatin, beyond its lipid-lowering effect, at therapeutic concentrations may affect early events of atherogenesis by inhibiting arterial myocyte migration and proliferation and by interfering with cellular cholesterol disposition, adds antiatherosclerotic properties to this drug. Fluvastatin possesses pharmacokinetic properties desirable for inhibitors of HMG-CoA reductase, and thus of cholesterol biosynthesis. Fluvastatin is almost completely absorbed after oral administration in all species, is largely extracted and biotransformed by the liver, and exhibits a short half-life. Furthermore, a major portion of fluvastatin and its metabolites is preferentially excreted into bile, thus minimizing the systemic burden. The drug and its metabolites are readily excreted and show no retention in body tissues. Safety of fluvastatin after acute and chronic administration was evaluated in various animal species. The results indicate that fluvastatin has different species-specific target organs at doses many times higher than those estimated in man. In conclusion, fluvastatin is a well tolerated and highly effective drug. Thus, it may be considered an important drug in the therapeutic armamentarium available for the treatment of hypercholesterolemia and for the prevention of atherosclerosis.

AB - Fluvastatin is the first entirely synthetic inhibitor of HMG-CoA reductase that has been extensively investigated. According to the studies presented in this review, fluvastatin is a potent inhibitor of HMG-CoA reductase in vitro, a potent inhibitor of cholesterol biosynthesis in cultured cells and in vivo in rats, and a potent hypocholesterolemic agent in several animal species. Inhibition of liver cholesterol synthesis by fluvastatin leads to increased expression of LDL receptors on the cell surface. This in turn leads to increased turnover in circulating LDL particles, thus decreasing total blood cholesterol. The observation that fluvastatin, beyond its lipid-lowering effect, at therapeutic concentrations may affect early events of atherogenesis by inhibiting arterial myocyte migration and proliferation and by interfering with cellular cholesterol disposition, adds antiatherosclerotic properties to this drug. Fluvastatin possesses pharmacokinetic properties desirable for inhibitors of HMG-CoA reductase, and thus of cholesterol biosynthesis. Fluvastatin is almost completely absorbed after oral administration in all species, is largely extracted and biotransformed by the liver, and exhibits a short half-life. Furthermore, a major portion of fluvastatin and its metabolites is preferentially excreted into bile, thus minimizing the systemic burden. The drug and its metabolites are readily excreted and show no retention in body tissues. Safety of fluvastatin after acute and chronic administration was evaluated in various animal species. The results indicate that fluvastatin has different species-specific target organs at doses many times higher than those estimated in man. In conclusion, fluvastatin is a well tolerated and highly effective drug. Thus, it may be considered an important drug in the therapeutic armamentarium available for the treatment of hypercholesterolemia and for the prevention of atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0029882348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029882348&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029882348

VL - 32

SP - 13

EP - 35

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - SUPPL A

ER -